Ophthalmic Consultants of Boston
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-08 | NCT04108156 | |
| An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED | Conjunctival Diseases, Conjunctivitis, Allergic, Hypersensitivity, Immediate, conjunctivitis, eye disorder, immune system disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07519902 | |
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06510816 | |
| A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-09-30 | NCT06769048 | |
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06635148 | |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration; nAMD | Recruiting | Phase 3 | 2026-09-29 | NCT07614776 | |
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | NCT03683251 | |
| ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06373731 | |
| A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 1 | 2026-09-03 | NCT03178149 | |
| A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Not stated | 2026-09-01 | NCT06346600 | |
| Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | Recruiting | Phase 1 / Phase 2 | 2026-08-28 | NCT05986864 | |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-08-19 | NCT04567550 | |
| Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-17 | NCT06087458 | |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Enrolling by invitation | Phase 2 | 2026-08-05 | NCT05296447 | |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD | Neovascular Age-Related Macular Degeneration (nAMD) | Enrolling by invitation | Phase 2 | 2026-08-05 | NCT05210803 | |
| Long-Term Follow Up of VOY-101 Non-nAMD Extension Study | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Enrolling by invitation | Not stated | 2026-06-22 | NCT07660640 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | NCT06996080 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | NCT06990399 | |
| A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT06722157 | |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | NCT06556368 | |
| A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-07 | NCT04850118 | |
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | diabetic macular edema | Active, not recruiting | Phase 2 | 2025-05-04 | NCT05387837 | |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Enrolling by invitation | Phase 2 | 2024-06-17 | NCT03999801 |